About Us

AgenTus Therapeutics, a biopharmaceutical company, is focused on the discovery, development, and commercialization of breakthrough “living drugs” to advance cures for cancer patients. AgenTus will employ naturally-derived and engineered receptors, specifically T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge human immune effector cells to seek and destroy cancer. AgenTus will also aim to advance adoptive cell therapy formats which would enable off-the-shelf living drugs.

At AgenTus, our plan is to move rapidly to the forefront with powerful adoptive cell therapy platforms that offer competitive advantages over current approaches, based on the following unique features:

Core platforms:
AgenTus will utilize enabling technologies, including the T-Rx™ platform, a discovery platform designed to identify, characterize and engineer new TCRs with optimal binding and functional properties. Our technologies will also be applied to enable CAR approaches to develop TCR and CAR living drugs. We will deploy a multi-platform approach to leverage the complementarity of CAR and TCR technologies.
Our novel drug targets:
AgenTus will pursue a series of cancer-specific drug targets, including Phosphopeptide Tumor Targets (PTTs), to advance novel therapeutics.
Our innovative drug development:
Using proprietary technologies, our drug development plans are designed to deliver living drugs in autologous and off-the-shelf formats that would be scalable, straightforward to administer, and effective for both solid and liquid tumors.

Advances in our understanding of the interactions between cancers, the tumor microenvironment, and the immune system have led to powerful new approaches to treat cancer.  AgenTus was formed as a subsidiary of Agenus Inc. to bring innovative living drugs to cancer patients.  Integrated platform will be employed to discover and develop novel living drugs to treat a broad range of cancers.

 
Back to Top